Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 18;135(2):97–107. doi: 10.1182/blood.2019003125

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

PMC Copyright notice

Figure 4. — Sirolimus treatment resulted in improved immune suppression discontinuation and improved patient-reported quality of life. (A) Cumulative incidence of complete discontinuation of all systemic immune suppressive medications, with death as competing risk event. (B) SF-36 physical component score (PCS) and mental component score (MCS) changes over time. (C) FACT-BMT total score over time. (D) FACT-BMT trial outcome index (TOI) score over time. Change from baseline to day 180 was significantly greater for sirolimus vs prednisone for SF-36 PCS (P = .012) and for FACT-BMT TOI (P = .034).